TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02246582

Intervention type: DEVICE
Group type: OTHER
Intervention: Enlite 3
Description: Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen \& arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.

Intervention type: DEVICE
Group type: OTHER
Intervention: Enlite 3
Description: Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen \& arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.

Intervention type: DEVICE
Group type: OTHER
Intervention: Guardian Mobile App

Intervention type: DEVICE
Group type: OTHER
Intervention: Guardian Mobile App

Intervention type: DEVICE
Group type: OTHER
Intervention: 640G Insulin Pump

Intervention type: DEVICE
Group type: OTHER
Intervention: 640G Insulin Pump
Study: NCT03441334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency rTMS
Description: Participants in the intervention group will receive 1200 stimuli at the intensity of 90% of resting motor threshold via an air-filmed coil placed on the vertex. The stimulation will be delivered across 24 sessions (in 10 weeks). Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Participants in the sham group will receive the same duration of stimulation via a sham coil placed on the vertex.Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
Study: NCT02008279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 mg CNTO 3157
Description: A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 mg CNTO 3157
Description: A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300 mg CNTO 3157
Description: 2 SC injections of CNTO 3157 providing a total dose of 300 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300 mg CNTO 3157
Description: 2 SC injections of CNTO 3157 providing a total dose of 300 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 600 mg CNTO 3157
Description: 4 SC injections of CNTO 3157 providing a total dose of 600 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 600 mg CNTO 3157
Description: 4 SC injections of CNTO 3157 providing a total dose of 600 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300 mg CNTO 3157
Description: 300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
Study: NCT01907542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stapled skin closure
Description: as above

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monocryl skin suture
Description: as above
Study: NCT00395863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multihance
Description: 0.5 M at a single injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 - Magnevist
Description: 0.5 M Magnevist at a single dose injection
Study: NCT00682448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo. Subjects will remain on placebo for 6 months.
Study: NCT01256151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam tablet
Description: 1 mg single dose of alprazolam conventional tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam sublingual
Description: 1 mg single dose of alprazolam sublingual tablet
Study: NCT04442971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Stimulation
Description: Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Stimulation
Description: Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Auditory Stimulation
Description: Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
Study: NCT02549430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Continuation of prior anastrozole 1mg/day orally in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Continuation of prior letrozole 2.5mg/day orally in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Continuation of prior exemestane 25mg/day orally in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
Study: NCT02171845

Intervention type: OTHER
Intervention: surgical biopsies
Study: NCT03862144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant/Palonosetron
Study: NCT01715220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual nitroglycerine
Description: A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sublingual nitroglycerine
Description: A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
Study: NCT01689675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer based pain management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer based pain management
Study: NCT00790686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of Memokath 051
Description: Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
Study: NCT03332914

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent therapy
Description: The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent therapy
Description: The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
Study: NCT02465983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-meso-19 T cells
Description: A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
Study: NCT03384862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills, with same appearance as intervention pills.
Study: NCT02475226

Intervention type: OTHER
Intervention: type of the brain injury
Description: epidural hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: epidural hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: epidural hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: subdural hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: subdural hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: subdural hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: subarachnoid hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: subarachnoid hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: subarachnoid hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: intraparenchymal hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: intraparenchymal hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: intraparenchymal hematoma

Intervention type: OTHER
Intervention: type of the brain injury
Description: scull fracture

Intervention type: OTHER
Intervention: type of the brain injury
Description: scull fracture

Intervention type: OTHER
Intervention: type of the brain injury
Description: scull fracture

Intervention type: OTHER
Intervention: type of the brain injury
Description: brain contusion

Intervention type: OTHER
Intervention: type of the brain injury
Description: brain contusion

Intervention type: OTHER
Intervention: type of the brain injury
Description: brain contusion
Study: NCT01782573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: (i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: (i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
Study: NCT03999723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.
Study: NCT01686776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 123 I-HSA + 125 I HSA
Description: Compare and validate the method of measuring albumine turnover rate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 123 I-HSA + 125 I HSA
Description: Compare and validate the method of measuring albumine turnover rate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 123 I-HSA + 125 I HSA
Description: Compare and validate the method of measuring albumine turnover rate
Study: NCT02650999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg intravenously (IV)
Study: NCT02389023

Intervention type: OTHER
Group type: OTHER
Intervention: standard gauze dressing
Description: Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care

Intervention type: OTHER
Group type: OTHER
Intervention: Prevena Incision Management system
Description: The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
Study: NCT01161355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: Tablets of AZD9668 and IV dose of \[C14\]AZD9668
Study: NCT04935892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slippers
Description: Patients in the intervention group wear slippers when out of bed
Study: NCT00844155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75 mg
Description: The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75 mg
Description: The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
Study: NCT01923142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Outer-Root-Sheath Melanocytes Suspension
Description: The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
Study: NCT03010306

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CASITA
Study: NCT02114411

Intervention type: PROCEDURE
Intervention: GastroPanel test
Description: Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).

Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
Study: NCT02080247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin care regimen with Calmoseptine ointment
Description: Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin care regimen with Destin ointment
Description: Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
Study: NCT02470468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC add on to SOC
Description: DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC and immune enhancers add on to SOC
Description: DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Chemotherapy
Description: SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
Study: NCT01180478

Intervention type: DEVICE
Group type: OTHER
Intervention: White Light
Description: White Light Cystoscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: Narrow Band Imaging
Description: Narrow Band Imaging
Study: NCT01993212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 12.5 mg or 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel 1.62%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Study: NCT04415957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Tape
Description: The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
Study: NCT00362414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Growth Factor
Description: 10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation
Study: NCT04591730

Intervention type: OTHER
Intervention: First time father questionnaire self-administration
Description: The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.

Intervention type: OTHER
Intervention: First time father questionnaire self-administration
Description: The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.

Intervention type: OTHER
Intervention: First time father questionnaire self-administration
Description: The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.
Study: NCT03104075

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein
Description: One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal Vaccine Polyvalent
Description: One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13
Study: NCT01505270

Intervention type: OTHER
Intervention: Retrospective case study
Description: Retrospective case study
Study: NCT02418780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice